21%), fatigue (25% vs.
20%), vomiting (23% vs.
8%), and abdominal pain (22% vs.
10%).
The FDA label recommends prophylactic loperamide during the first 56 days of therapy, and as needed thereafter to help manage diarrhea.
The most common grade 3 to 4 adverse event was diarrhea (neratinib, 40% vs.
placebo, 2%).
All other grade 3 to 4 adverse events occurred in 2% or less of patients.
There are no studies comparing different regimens in patients with node-negative, small, HER2-positive breast tumors.
The following two large single-arm studies demonstrated outcomes that appear to be superior to previous results in similar patients who did not receive adjuvant therapy.